NORTH HAVEN, Conn.--(BUSINESS WIRE)--Apr. 21, 2009-- Covidien (NYSE: COV, BSX: COV), a leading global provider of healthcare products, today announced that it has filed a lawsuit in the United States District Court for the District of Delaware against Davol, Inc., a wholly owned subsidiary of C.R. Bard, relating to its mesh fixation device and applier. The lawsuit contends that Davol’s recently released Sorbafix™ device infringes multiple claims of Covidien’s U.S. Patent Number 6,562,051.
“We will vigorously protect our intellectual property,” said Dave Motley, Global Surgical Franchise and Portfolio Management, Covidien.
The patent generally relates to a system for controllably discharging fasteners from an applicator. Covidien is asking the federal court to enjoin Davol from continuing to make and sell its Sorbafix™ device, as well as for compensatory damages.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Source: Covidien
Covidien
Joel Weinberg, 203-492-5576 Manager – Media Relations Surgical Devices joel.weinberg@covidien.com or
Coleman Lannum, CFA, 508-452-4343 Vice President Investor Relations cole.lannum@covidien.com or
Bruce Farmer, 508-452-4372 Vice President Public Relations bruce.farmer@covidien.com or
Brian Nameth, 508-452-4363 Director Investor Relations brian.nameth@covidien.com
